tirzepatide dose escalation Zepbound® Dosage Guide What to expect after your

Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study

I recommend a consistent weight loss of 1.5 to 2 lbs per week as a target

Thyroid concerns have been flagged in preclinical studies but lack confirmed clinical significance in human populations receiving standard therapeutic doses

Rather, it may provide complementary cardiovascular benefits in appropriate patient populations, particularly those with obesity or type 2 diabetes who have not achieved adequate lipid control with lifestyle modifications and standard pharmacotherapy alone

Guidance for Prescribing Glucagon-like peptide 1 (GLP 1) agonists

have issued similar warnings as the popularity of Ozempic and other weight-loss drugs has risen